Premium
Effect of obesity and weight reduction on biliary cholesterol saturation and the response to chenodeoxycholic acid *
Author(s) -
REUBEN A.,
QURESHI Y.,
MURPHY G. M.,
DOWLING R. H.
Publication year - 1986
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1986.tb01320.x
Subject(s) - chenodeoxycholic acid , medicine , dieting , gallstones , endocrinology , obesity , weight loss , bile acid , cholesterol , gastroenterology
. Biliary cholesterol saturation indices (SI's) were measured in fasting duodenal bile from (i) obese and non‐obese individuals with and without cholesterol gallstones, (ii) obese individuals undergoing weight reduction and (iii) obese gallstone patients receiving chenodeoxycholic acid (CDCA) therapy. Biliary lipid secretion rates were also measured in three obese subjects before and during 11 days starvation. The mean SI in fifteen non‐obese controls (0·89 ± SEM 0·06) was significantly lower than that in the twenty‐four obese without (1·14 ± 0·07; P < 0·01), and in the twenty‐nine non‐obese with gallstones (1·30 ± 0·05; P < 0·001) while in sixteen obese gallstone patients, the mean SI of 1·55 ± 0·06 was significantly higher than that seen in the other three groups ( P < 0·01–0·001). Although fifteen obese subjects lost 15% of their initial body weight during dieting, this did not change their SI's consistently. However in three obese individuals, total starvation did reduce the SI's and significantly lowered the biliary cholesterol secretion rate. Ten obese gallstone patients responded to 15·8 ± 0·3 mg CDCA kg ‐1 day ‐1 by developing unsaturated fasting duodenal bile (SI 0·89 ± 0·04). A further increase in CDCA dose to 19·0 ± 0·7 mg kg ‐1 day ‐1 , as a result of reducing body weight, was more effective in lowering SI's (0·75 ± 0·06, range 0·51–1·0) than that achieved by increasing the dose to 18·9 ± 0·46 mg kg ‐1 day ‐1 through more capsules per day (SI o·89 ± 0·03, range 0·67 ‐ 1·25). These studies show that (i) biliary cholesterol SI's are greater when obesity and gallstones occur together than in either obesity or gallstones alone, and (ii) although weight loss in obese individuals does not consistently alter biliary cholesterol SI's, it may be beneficial in obese patients receiving CDCA therapy for gallstone dissolution.